← Eichor
Condition: Systemic Lupus Erythematosus Disease Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Systemic Lupus Erythematosus Disease

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of Neonatal IgG Fc Receptor Expression in Natural Killer T Cells Expressing an Invariant T Receptor : Implication
Phase N/A · 1 location(s) · University Hospital, Tours · NCT05859191National Systemic Lupus Erythematosus Prospective Cohort, Saudi Arabia
Phase N/A · 1 location(s) · King Saud University · NCT04604990An Exploratory Clinical Study of SCAR02 Targeting BCMA and CD19 for the Treatment of Refractory Autoimmune Diseases
NA · 1 location(s) · The First Affiliated Hospital of University of Science and T · NCT06503224Study of CD19 CAR-T Therapy for Refractory SLE
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT07403097An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus
EARLY_Phase 1 · 1 location(s) · Changhai Hospital · NCT06010472AGR+PNI as Predictors of Systemic Lupus Erythematosus Disease Activity
Phase N/A · 1 location(s) · Sohag University · NCT07043153CorEvitas Systemic Lupus Erythematosus (SLE) Drug Safety and Effectiveness Registry
Phase N/A · 1 location(s) · CorEvitas · NCT06804057Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users
Phase N/A · 1 location(s) · AstraZeneca · NCT06659029Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE
Phase 1 · 1 location(s) · The Children's Hospital of Zhejiang University School of Med · NCT07233642Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Det
Phase N/A · 1 location(s) · National Institute of Arthritis and Musculoskeletal and Skin · NCT05567198Observational Study of Pediatric Rheumatic and Immunologic Diseases in China: The CAPRID Registry
Phase N/A · 9 location(s) · Peking Union Medical College Hospital · NCT06417502Blinatumomab in Refractory Active Childhood Systemic Lupus Erythematosus
Phase 1 · 2 location(s) · Mao Jianhua · NCT06789107" TREX1 Gene Mutations and Their Role in Systemic Lupus Erythematosus
Phase N/A · 1 location(s) · South Valley University · NCT07397728Meir Medical Center Rheumatologic Biobank
Phase N/A · 1 location(s) · Meir Medical Center · NCT03473912Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus
Phase 1 · 1 location(s) · Chinese SLE Treatment And Research Group · NCT06881290Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associate
Phase 1 · 1 location(s) · IRIS Research and Development, LLC · NCT06581562Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases
EARLY_Phase 1 · 1 location(s) · Juventas Cell Therapy Ltd. · NCT06316791A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
Phase 1 · 14 location(s) · CRISPR Therapeutics · NCT06925542Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA
Phase 1 · 7 location(s) · Neutrolis · NCT07237659CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory
Phase 1 · 1 location(s) · Beijing GoBroad Hospital · NCT06822881Transforming Care for Individuals With Childhood-onset Systemic Lupus Erythematosus
NA · 7 location(s) · Michigan State University · NCT06232304Efficacy and Safety of CD19 UCAR T Cells in Refractory Systemic Lupus Erythematosus
Phase 1 · 1 location(s) · The Children's Hospital of Zhejiang University School of Med · NCT06691152Trial of Belimumab in Early Lupus
Phase 4 · 1 location(s) · Northwell Health · NCT03543839Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
Phase N/A · 1 location(s) · Institut National de la Santé Et de la Recherche Médicale, F · NCT04902807A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Jap
Phase 1 · 28 location(s) · GlaxoSmithKline · NCT06576271Early Myocardial Dysfunction Helps Identify Severe Refractory Pediatric Lupus
Phase N/A · 1 location(s) · Shanghai Jiao Tong University School of Medicine · NCT07425730CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
Phase 1/Phase 2 · 1 location(s) · Children's Hospital of Philadelphia · NCT06839976Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus
Phase 1/Phase 2 · 1 location(s) · Beijing GoBroad Hospital · NCT06585514Pregnancies Before the Diagnosis of Systemic Lupus Erythematosus
Phase N/A · 2 location(s) · University of Algiers · NCT07148115A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Ery
Phase 4 · 114 location(s) · GlaxoSmithKline · NCT06411249
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.